Steve Young

Steve has been in scientific, technical and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences (subsequently FLX Bio). He was the first scientist at Flexus and spearheaded a ground-up build of the biology and IT/informatics functions, including hiring the team and establishing the SAR data infrastructure which enabled the successful IDO inhibitor program. Previously, as Executive Director at Amgen, heading the Discovery Technologies Department, Steve led a group of 110 scientists across five geographical sites to enact key technical functions including Research Automation and Technology, Materials Management, HTS, Bioassay Technology and Target Discovery/Validation. Steve started at Amgen in 2004, following the acquisition of Tularik, where he had been leading the Lead Discovery Function (Small Molecule and Genomic Screening, Automation and SAR data generation). He moved to Seattle to establish the first automated screening laboratory at Amgen, Washington in 2006.

In 2008 he moved again to Massachusetts to serve as the inaugural site head at Amgen’s east coast research hub in Cambridge, focusing on Amgen’s growth in a key scientific locale and acting as Amgen’s senior representative for academia, industry and government affairs. Prior to moving to the U.S. in 2001, Steve headed the HTS Department at Roche U.K., having started his career earlier at Glaxo. Steve holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the University of Bristol and a diploma in Business Administration from the Open University. He is currently on the Board of Directors of the Society for Laboratory Automation and Screening.